Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: Novel targets for antipsychotic drugs

Progress in Brain Research

Volumn 211, Issue , 2014, Pages 113-139

  Fuxe, Kjell ^a   Borroto Escuela, Dasiel O ^a   Tarakanov, Alexander O ^b   Romero Fernandez, Wilber ^a   Ferraro, Luca ^c   Tanganelli, Sergio ^c   Perez Alea, Mileidys ^d   Di Palma, Michael ^a,e   Agnati, Luigi F ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST PETERSBURG INSTITUTE FOR INFORMATICS AND AUTOMATION   (Russian Federation)

^c UNIVERSITY OF FERRARA   (Italy)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF URBINO   (Italy)

^f IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

D2 receptors; Heteroreceptor complexes; Receptor receptor interactions; Schizophrenia; Ventral striatum

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ADENOSINE A2A RECEPTOR; BETA ARRESTIN 2; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; LYSERGIDE; NEUROLEPTIC AGENT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; OXYTOCIN RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; DOPAMINE;

ALLOSTERISM; ARTICLE; BRAIN CORTEX; COMPLEX FORMATION; CORPUS STRIATUM; DRUG MECHANISM; EMOTION; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; HETERORECEPTOR COMPLEX; HORMONE BINDING; HUMAN; LIMBIC CORTEX; MOLECULAR RECOGNITION; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; PHASE 2 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR RECEPTOR INTERACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; THALAMUS DORSOMEDIAL NUCLEUS; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMANS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; VENTRAL STRIATUM;

EID: 84904679945     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63425-2.00005-2     Document Type: Chapter

References (122)

1. Agnati L.F., Fuxe K., Benfenati F., Battistini N. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites. Acta Physiol. Scand. 1983, 119:459-461.
2. Agnati L.F., Franzen O., Ferre S., Leo G., Franco R., Fuxe K. Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. J. Neural Transm. Suppl. 2003, 65:1-28.
3. Agnati L.F., Barlow P., Ghidoni R., Borroto-Escuela D.O., Guidolin D., Fuxe K. Possible genetic and epigenetic links between human inner speech, schizophrenia and altruism. Brain Res. 2012, 1476:38-57.
4. Albizu L., Holloway T., Gonzalez-Maeso J., Sealfon S.C. Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 2011, 61:770-777.
5. Allen J.A., Yost J.M., Setola V., Chen X., Sassano M.F., Chen M., Peterson S., Yadav P.N., Huang X.P., Feng B., Jensen N.H., Che X., Bai X., Frye S.V., Wetsel W.C., Caron M.G., Javitch J.A., Roth B.L., Jin J. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. U.S.A 2011, 108:18488-18493.
6. Anden N.E., Corrodi H., Fuxe K., Hokfelt T. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Br. J. Pharmacol. 1968, 34:1-7.
7. Anden N.E., Corrodi H., Fuxe K. Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J. Pharmacol. Exp. Ther. 1971, 179:236-249.
8. Anden N.E., Corrodi H., Fuxe K., Meek J.L. Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors. Eur. J. Pharmacol. 1974, 25:176-184.
9. Andersen M.B., Fuxe K., Werge T., Gerlach J. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav. Pharmacol. 2002, 13:639-644.
10. Antonelli T., Fuxe K., Agnati L., Mazzoni E., Tanganelli S., Tomasini M.C., Ferraro L. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. J. Neurol. Sci. 2006, 248:16-22.
11. Arranz M.J., Munro J., Sham P., Kirov G., Murray R.M., Collier D.A., Kerwin R.W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 1998, 32:93-99.
12. Azdad K., Gall D., Woods A.S., Ledent C., Ferre S., Schiffmann S.N. Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 2009, 34:972-986.
13. Borroto-Escuela D.O., Marcellino D., Narvaez M., Flajolet M., Heintz N., Agnati L., Ciruela F., Fuxe K. A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R. Biochem. Biophys. Res. Commun. 2010, 394:222-227.
14. Borroto-Escuela D.O., Romero-Fernandez W., Tarakanov A.O., Gomez-Soler M., Corrales F., Marcellino D., Narvaez M., Frankowska M., Flajolet M., Heintz N., Agnati L.F., Ciruela F., Fuxe K. Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem. Biophys. Res. Commun. 2010, 402:801-807.
15. Borroto-Escuela D.O., Romero-Fernandez W., Tarakanov A.O., Marcellino D., Ciruela F., Agnati L.F., Fuxe K. Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers. Biochem. Biophys. Res. Commun. 2010, 401:605-610.
16. Borroto-Escuela D.O., Romero-Fernandez W., Tarakanov A.O., Ciruela F., Agnati L.F., Fuxe K. On the existence of a possible A2A-D2-beta-Arrestin2 complex: A2A agonist modulation of D2 agonist-induced beta-arrestin2 recruitment. J. Mol. Biol. 2011, 406:687-699.
17. Borroto-Escuela D.O., Tarakanov A.O., Guidolin D., Ciruela F., Agnati L.F., Fuxe K. Moonlighting characteristics of G protein-coupled receptors: focus on receptor heteromers and relevance for neurodegeneration. IUBMB Life 2011, 63:463-472.
18. Borroto-Escuela D.O., Van Craenenbroeck K., Romero-Fernandez W., Guidolin D., Woods A.S., Rivera A., Haegeman G., Agnati L.F., Tarakanov A.O., Fuxe K. Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions. Biochem. Biophys. Res. Commun. 2011, 404:928-934.
19. Borroto-Escuela D.O., Romero-Fernandez W., Mudo G., Perez-Alea M., Ciruela F., Tarakanov A.O., Narvaez M., Di Liberto V., Agnati L.F., Belluardo N., Fuxe K. Fibroblast growth factor receptor 1-5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity. Biol. Psychiatry 2012, 71:84-91.
20. Borroto-Escuela D.O., Flajolet M., Agnati L.F., Greengard P., Fuxe K. Bioluminescence resonance energy transfer methods to study g protein-coupled receptor-receptor tyrosine kinase heteroreceptor complexes. Methods Cell Biol. 2013, 117:141-164.
21. Borroto-Escuela D.O., Ravani A., Tarakanov A.O., Brito I., Narvaez M., Romero-Fernandez W., Corrales F., Agnati L.F., Tanganelli S., Ferraro L., Fuxe K. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem. Biophys. Res. Commun. 2013, 435:140-146.
22. Borroto-Escuela D.O., Romero-Fernandez W., Garriga P., Ciruela F., Narvaez M., Tarakanov A.O., Palkovits M., Agnati L.F., Fuxe K. G protein-coupled receptor heterodimerization in the brain. Methods Enzymol. 2013, 521:281-294.
23. Borroto-Escuela D.O., Romero-Fernandez W., Narvaez M., Oflijan J., Agnati L.F., Fuxe K. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochem. Biophys. Res. Commun. 2014, 443:278-284.
24. Borroto-Escuela, D.O., Romero-Fernandez, W., Carrera Pérez, D., Agnati, L.F., Pérez de la Mora, M., Fuxe, K., Dynamic modulation of dopamine D2-oxytocin heteroreceptor complexes signal in HEK293 and striatal primary culture cells (unpublished).
25. Bouvier M., Heveker N., Jockers R., Marullo S., Milligan G. BRET analysis of GPCR oligomerization: newer does not mean better. Nat. Methods 2007, 4:3-4. author reply 4.
26. Bujanow W. Hormones in the treatment of psychoses. Br. Med. J. 1972, 4:298.
27. Caldwell H.K., Stephens S.L., Young W.S. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol. Psychiatry 2009, 14:190-196.
28. Carriba P., Navarro G., Ciruela F., Ferre S., Casado V., Agnati L., Cortes A., Mallol J., Fuxe K., Canela E.I., Lluis C., Franco R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods 2008, 5:727-733.
29. Chase T.N., Bibbiani F., Oh J.D. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res. 2003, 5:139-146.
30. Ciruela F., Burgueno J., Casado V., Canals M., Marcellino D., Goldberg S.R., Bader M., Fuxe K., Agnati L.F., Lluis C., Franco R., Ferre S., Woods A.S. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem. 2004, 76:5354-5363.
31. Ciruela F., Vilardaga J.P., Fernandez-Duenas V. Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends Biotechnol. 2010, 28:407-415.
32. Colpaert F.C. Discovering risperidone: the LSD model of psychopathology. Nat. Rev. Drug Discov. 2003, 2:315-320.
33. Dahlstroem A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. Suppl. 1964, (Suppl. 232):1-55.
34. Dahlstroem A., Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal neuron systems. Acta Physiol. Scand. Suppl. 1965, (Suppl. 247):1-36.
35. De Bartolomeis A., Buonaguro E.F., Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl) 2013, 225:1-19.
36. Delille H.K., Becker J.M., Burkhardt S., Bleher B., Terstappen G.C., Schmidt M., Meyer A.H., Unger L., Marek G.J., Mezler M. Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 2012, 62:2184-2191.
37. Delille H.K., Mezler M., Marek G.J. The two faces of the pharmacological interaction of mGlu2 and 5-HT(2)A - relevance of receptor heterocomplexes and interaction through functional brain pathways. Neuropharmacology 2013, 70:296-305.
38. Diaz-Cabiale Z., Hurd Y., Guidolin D., Finnman U.B., Zoli M., Agnati L.F., Vanderhaeghen J.J., Fuxe K., Ferre S. Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport 2001, 12:1831-1834.
39. El Asmar L., Springael J.Y., Ballet S., Andrieu E.U., Vassart G., Parmentier M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 2005, 67:460-469.
40. Feifel D. Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 2012, 37:304-305.
41. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68:678-680.
42. Fernandez-Duenas V., Gomez-Soler M., Jacobson K.A., Santhosh Kumar T., Fuxe K., Borroto-Escuela D.O., Ciruela F. Molecular determinants of A2AR-D2R allosterism: Role of the intracellular loop 3 of the D2R. J. Neurochem. 2014, 123:373-384.
43. Ferraro L., Tomasini M.C., Mazza R., Fuxe K., Fournier J., Tanganelli S., Antonelli T. Neurotensin receptors as modulators of glutamatergic transmission. Brain Res. Rev. 2008, 58:365-373.
44. Ferraro L., Tomasini M.C., Beggiato S., Guerrini R., Salvadori S., Fuxe K., Calza L., Tanganelli S., Antonelli T. Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders. Mini Rev. Med. Chem. 2009, 9:1429-1438.
45. Fischer G., Schirrmacher R., Wangler B., Wangler C. Radiolabeled heterobivalent peptidic ligands: an approach with high future potential for in vivo imaging and therapy of malignant diseases. ChemMedChem 2013, 8:883-890.
46. Flajolet M., Wang Z., Futter M., Shen W., Nuangchamnong N., Bendor J., Wallach I., Nairn A.C., Surmeier D.J., Greengard P. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
47. Fribourg M., Moreno J.L., Holloway T., Provasi D., Baki L., Mahajan R., Park G., Adney S.K., Hatcher C., Eltit J.M., Ruta J.D., Albizu L., Li Z., Umali A., Shim J., Fabiato A., Mackerell A.D., Brezina V., Sealfon S.C., Filizola M., Gonzalez-Maeso J., Logothetis D.E. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011, 147:1011-1023.
48. Fuxe K. Cellular localization of monoamines in the median eminence and in the infundibular stem of some mammals. Acta Physiol. Scand. 1963, 58:383-384.
49. Fuxe K. Cellular localization of monoamines in the median eminence and the infundibular stem of some mammals. Z. Zellforsch. Mikrosk. Anat. 1964, 61:710-724.
50. Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. IV. distribution of monoamine nerve terminals in the central nervous system. Acta Physiol. Scand. Suppl. 1965, (Suppl. 247):37.
51. Fuxe K., Agnati L.F. Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 1985, 5:441-482.
52. Fuxe K., Holmstedt B., Jonsson G. Effects of 5-methoxy-N, N-dimethyltryptamine on central monoamine neurons. Eur. J. Pharmacol. 1972, 19:25-34.
53. Fuxe K., Agnati L.F., Benfenati F., Celani M., Zini I., Zoli M., Mutt V. Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J. Neural Transm. Suppl. 1983, 18:165-179.
54. Fuxe K., O'connor W.T., Antonelli T., Osborne P.G., Tanganelli S., Agnati L.F., Ungerstedt U. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc. Natl. Acad. Sci. U.S.A 1992, 89:5591-5595.
55. Fuxe K., Von Euler G., Agnati L.F., Merlo Pich E., O'connor W.T., Tanganelli S., Li X.M., Tinner B., Cintra A., Carani C., et al. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. N. Y. Acad. Sci. 1992, 668:186-204.
56. Fuxe K., Ferre S., Zoli M., Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 1998, 26:258-273.
57. Fuxe K., Agnati L.F., Jacobsen K., Hillion J., Canals M., Torvinen M., Tinner-Staines B., Staines W., Rosin D., Terasmaa A., Popoli P., Leo G., Vergoni V., Lluis C., Ciruela F., Franco R., Ferre S. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 2003, 61:S19-S23.
58. Fuxe K., Canals M., Torvinen M., Marcellino D., Terasmaa A., Genedani S., Leo G., Guidolin D., Diaz-Cabiale Z., Rivera A., Lundstrom L., Langel U., Narvaez J., Tanganelli S., Lluis C., Ferre S., Woods A., Franco R., Agnati L.F. Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J. Neural Transm. 2007, 114:49-75.
59. Fuxe K., Marcellino D., Genedani S., Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov. Disord. 2007, 22:1990-2017.
60. Fuxe K., Marcellino D., Rivera A., Diaz-Cabiale Z., Filip M., Gago B., Roberts D.C., Langel U., Genedani S., Ferraro L., De La Calle A., Narvaez J., Tanganelli S., Woods A., Agnati L.F. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev. 2008, 58:415-452.
61. Fuxe K., Marcellino D., Woods A.S., Giuseppina L., Antonelli T., Ferraro L., Tanganelli S., Agnati L.F. Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia. J. Neural Transm. 2009, 116:923-939.
62. Fuxe K., Marcellino D., Borroto-Escuela D.O., Guescini M., Fernandez-Duenas V., Tanganelli S., Rivera A., Ciruela F., Agnati L.F. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:e18-e42.
63. Fuxe K., Borroto-Escuela D.O., Marcellino D., Romero-Fernandez W., Frankowska M., Guidolin D., Filip M., Ferraro L., Woods A.S., Tarakanov A., Ciruela F., Agnati L.F., Tanganelli S. GPCR heteromers and their allosteric receptor-receptor interactions. Curr. Med. Chem. 2012, 19:356-363.
64. Fuxe K., Borroto-Escuela D.O., Romero-Fernandez W., Ciruela F., Manger P., Leo G., Diaz-Cabiale Z., Agnati L.F. On the role of volume transmission and receptor-receptor interactions in social behaviour: focus on central catecholamine and oxytocin neurons. Brain Res. 2012, 1476:119-131.
65. Fuxe K., Borroto-Escuela D.O., Romero-Fernandez W., Diaz-Cabiale Z., Rivera A., Ferraro L., Tanganelli S., Tarakanov A.O., Garriga P., Narvaez J.A., Ciruela F., Guescini M., Agnati L.F. Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks. Front. Physiol. 2012, 3:136.
66. Fuxe K., Borroto-Escuela D.O., Romero-Fernandez W., Palkovits M., Tarakanov A.O., Ciruela F., Agnati L.F. Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the g protein-coupled receptor field. Neuropsychopharmacology 2014, 39:131-155.
67. Gamulin V., Rinkevich B., Schacke H., Kruse M., Muller I.M., Muller W.E. Cell adhesion receptors and nuclear receptors are highly conserved from the lowest metazoa (marine sponges) to vertebrates. Biol. Chem. Hoppe Seyler 1994, 375:583-588.
68. George S.R., O'dowd B.F. A novel dopamine receptor signaling unit in brain: heterooligomers of D1 and D2 dopamine receptors. ScientificWorldJournal 2007, 7:58-63.
69. George S.R., O'dowd B.F., Lee S.P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov. 2002, 1:808-820.
70. Gingrich B., Liu Y., Cascio C., Wang Z., Insel T.R. Dopamine D2 receptors in the nucleus accumbens are important for social attachment in female prairie voles (Microtus ochrogaster). Behav. Neurosci. 2000, 114:173-183.
71. Gonzalez-Maeso J., Yuen T., Ebersole B.J., Wurmbach E., Lira A., Zhou M., Weisstaub N., Hen R., Gingrich J.A., Sealfon S.C. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J. Neurosci. 2003, 23:8836-8843.
72. Gonzalez-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., Lira A., Bradley-Moore M., Ge Y., Zhou Q., Sealfon S.C., Gingrich J.A. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53:439-452.
73. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
74. Green J.J., Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 2010, 7:250-257.
75. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M.E., Mallol J., Canela E.I., Zoli M., Agnati L.F., Ibanez C.F., Lluis C., Franco R., Ferre S., Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 2002, 277:18091-18097.
76. Insel T.R., Young L.J. The neurobiology of attachment. Nat. Rev. Neurosci. 2001, 2:129-136.
77. Jeffery C.J. Moonlighting proteins. Trends Biochem. Sci. 1999, 24:8-11.
78. Kinkead B., Nemeroff C.B. Neurotensin: an endogenous antipsychotic?. Curr. Opin. Pharmacol. 2002, 2:99-103.
79. Kirov G., Grozeva D., Norton N., Ivanov D., Mantripragada K.K., Holmans P., International Schizophrenia Consortium, Wellcome Trust Case Control, Craddock N., Owen M.J., O'donovan M.C. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum. Mol. Genet. 2009, 18:1497-1503.
80. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005, 30:1883-1894.
81. Lennertz L., Wagner M., Wolwer W., Schuhmacher A., Frommann I., Berning J., Schulze-Rauschenbach S., Landsberg M.W., Steinbrecher A., Alexander M., Franke P.E., Pukrop R., Ruhrmann S., Bechdolf A., Gaebel W., Klosterkotter J., Hafner H., Maier W., Mossner R. A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:117-124.
82. Lewis D.A., Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int. Rev. Neurobiol. 2007, 78:109-131.
83. Li X.M., Hedlund P.B., Fuxe K. Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections. Neuroreport 1994, 5:1621-1624.
84. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 1998, 44:1099-1117.
85. Limbird L.E., Meyts P.D., Lefkowitz R.J. Beta-adrenergic receptors: evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 1975, 64:1160-1168.
86. Liu F., Wan Q., Pristupa Z.B., Yu X.M., Wang Y.T., Niznik H.B. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 2000, 403:274-280.
87. Lukasiewicz S., Polit A., Kedracka-Krok S., Wedzony K., Mackowiak M., Dziedzicka-Wasylewska M. Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim. Biophys. Acta 2010, 1803:1347-1358.
88. Lukasiewicz S., Faron-Gorecka A., Kedracka-Krok S., Dziedzicka-Wasylewska M. Effect of clozapine on the dimerization of serotonin 5-HT(2A) receptor and its genetic variant 5-HT(2A)H425Y with dopamine D(2) receptor. Eur. J. Pharmacol. 2011, 659:114-123.
89. Marshall F.H., White J., Main M., Green A., Wise A. GABA(B) receptors function as heterodimers. Biochem. Soc. Trans. 1999, 27:530-535.
90. Meltzer H.Y. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb. Exp. Pharmacol. 2012, 212:87-124.
91. Meltzer H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64:393-406.
92. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251:238-246.
93. Meltzer H.Y., Arvanitis L., Bauer D., Rein W., Meta-Trial Study Group Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2004, 161:975-984.
94. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
95. Morelli M., Blandini F., Simola N., Hauser R.A. A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinsons Dis. 2012, 2012:489853.
96. Moreno J.L., Holloway T., Albizu L., Sealfon S.C., Gonzalez-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci. Lett. 2011, 493:76-79.
97. Moreno J.L., Muguruza C., Umali A., Mortillo S., Holloway T., Pilar-Cuellar F., Mocci G., Seto J., Callado L.F., Neve R.L., Milligan G., Sealfon S.C., Lopez-Gimenez J.F., Meana J.J., Benson D.L., Gonzalez-Maeso J. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A.mGlu2) receptor heteromerization and its psychoactive behavioral function. J. Biol. Chem. 2012, 287:44301-44319.
98. Muguruza C., Moreno J.L., Umali A., Callado L.F., Meana J.J., Gonzalez-Maeso J. Dysregulated 5-HT(2)A receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur. Neuropsychopharmacol. 2013, 23:852-864.
99. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
100. Perreault M.L., Hasbi A., O'dowd B.F., George S.R. Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology 2014, 39:156-168.
101. Rimondini R., Ferre S., Ogren S.O., Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 1997, 17:82-91.
102. Romero-Fernandez W., Borroto-Escuela D.O., Agnati L.F., Fuxe K. Evidence for the existence of dopamine d2-oxytocin receptor heteromers in the ventral and dorsal striatum with facilitatory receptor-receptor interactions. Mol. Psychiatry 2013, 18:849-850.
103. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.F., Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006, 29:647-654.
104. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Brain Res. Rev. 2000, 31:320-329.
105. Tanganelli S., O'connor W.T., Ferraro L., Bianchi C., Beani L., Ungerstedt U., Fuxe K. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 1994, 60:649-657.
106. Tanganelli S., Sandager Nielsen K., Ferraro L., Antonelli T., Kehr J., Franco R., Ferre S., Agnati L.F., Fuxe K., Scheel-Kruger J. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism Relat. Disord. 2004, 10:273-280.
107. Tanganelli S., Antonelli T., Tomasini M.C., Beggiato S., Fuxe K., Ferraro L. Relevance of dopamine D(2)/neurotensin NTS1 and NMDA/neurotensin NTS1 receptor interaction in psychiatric and neurodegenerative disorders. Curr. Med. Chem. 2012, 19:304-316.
108. Tarakanov A.O., Fuxe K.G. Triplet puzzle: homologies of receptor heteromers. J. Mol. Neurosci. 2010, 41:294-303.
109. Tarakanov A.O., Fuxe K.G. The triplet puzzle of homologies in receptor heteromers exists also in other types of protein-protein interactions. J. Mol. Neurosci. 2011, 44:173-177.
110. Tarakanov A.O., Fuxe K.G. Integrin triplets of marine sponges in the murine and human MHCI-CD8 interface and in the interface of human neural receptor heteromers and subunits. Springerplus 2013, 2:128.
111. Tarakanov A.O., Fuxe K.G., Borroto-Escuela D.O. Integrin triplets of marine sponges in human D2 receptor heteromers. J. Recept. Signal Transduct. Res. 2012, 32:202-208.
112. Trifilieff P., Rives M.L., Urizar E., Piskorowski R.A., Vishwasrao H.D., Castrillon J., Schmauss C., Slattman M., Gullberg M., Javitch J.A. Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 2011, 51:111-118.
113. Uvnas-Moberg K., Petersson M. Oxytocin, a mediator of anti-stress, well-being, social interaction, growth and healing. Z. Psychosom. Med. Psychother. 2005, 51:57-80.
114. Vollenweider F.X. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 1998, 31(Suppl. 2):92-103.
115. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9:3897-3902.
116. Von Euler G., Fuxe K. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes. Acta Physiol. Scand. 1987, 131:625-626.
117. Von Euler G., Meister B., Hokfelt T., Fuxe K. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain. Acta Physiol. Scand. 1989, 137:309-310.
118. Wang R., Natarajan K., Margulies D.H. Structural basis of the CD8ab/MHCI interaction: focused recognition orients CD8b to a T cell proximal position. J. Immunol. 2009, 183:2554-2564.
119. Wang M., Wong A.H., Liu F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res. 2012, 1476:154-163.
120. Woods A.S., Ciruela F., Fuxe K., Agnati L.F., Lluis C., Franco R., Ferre S. Role of electrostatic interaction in receptor-receptor heteromerization. J. Mol. Neurosci. 2005, 26:125-132.
121. Young L.J., Wang Z. The neurobiology of pair bonding. Nat. Neurosci. 2004, 7:1048-1054.
122. Young L.J., Lim M.M., Gingrich B., Insel T.R. Cellular mechanisms of social attachment. Horm. Behav. 2001, 40:133-138.